DeepVessel AI Named to MIT Technology Review's TR50 List and Files IPO Prospectus

On June 29, the Global Smart Companies Summit was held in Hangzhou, where the “MIT Technology Review’s 50 Smartest Companies (TR50)” list was officially unveiled.Leveraging its technological innovation and commercialization capabilities in the field of smart healthcare, TomoDeep has stood out from the competition and been named one of MIT Technology Review’s 50 Smart Companies!

Tumashenwei Founder and CEO Zhong Xin Takes the Stage to Accept the Award

Tumashenwei was named one of the “50 Smartest Companies” for the following reason: Its multiple intelligent diagnostic systems have demonstrated higher sensitivity in result interpretation than most radiologists, along with a low false-positive rate, positioning them among the top-performing products of their kind globally.

How to Define a “Smart” Company? As MIT Technology Review puts it, this may sound difficult, but you will know it when you see one. When such a company commercializes a truly innovative technology, something remarkable happens:As the market leader’s position is either consolidated or displaced by other companies, competitors must redefine or rethink their strategies.

Since 2010, MIT Technology Review has annually selected the “50 Smartest Companies.” The core criterion for this ranking is not short-term revenue figures.Assessment of Innovation Capability Based on Emerging Technologies: Has the company made any major innovations in the past year that will redefine its field?

MIT Technology Review’s Complete List of 50 Smartest Companies

From the perspective of listed companies, “AI” is nearly ubiquitous, and the resulting technological evolution and innovation in computing power, cloud infrastructure, chips, and more have further given rise to a brand-new “AI civilization.” Companies such as Alibaba Cloud, Qualcomm, NVIDIA, and iFlytek are included on the list, alongside emerging AI enterprises like Heren Technology, Yixue Squirrel AI, SenseTime, and Yitu Technology.

Furthermore, the life sciences sector stands out as a major highlight on the list, encompassing gene editing, new drug development, pharmaceutical professional services, medical devices, and equipment. Notable companies featured include WuXi AppTec, Fosun Kite Biotechnology, and CytoTherapeutics.

As a company applying AI technology in the medical field, Tuma Shenwei has been selected as one of the 50 Smartest Companies, leading in technological innovation, service innovation, and business model innovation.

Tumashenwei’s vision is to leverage cutting-edge deep learning technologies to propel medicine into the era of artificial intelligence. We have witnessed the industry’s skepticism and resistance toward AI, as well as its subsequent openness and acceptance. Throughout this transition, both Tumashenwei and our peers have made significant contributions.More and more clinicians are embracing AI, which is becoming a powerful assistant for doctors.

Zhong Xin, Founder and CEO of Tumavis, at the Summit

At the “Global Smart Companies Summit,” Zhong Xin, Founder and CEO of Tuma Shenwei, stated that malignant tumors remain a significant factor affecting human survival. “We aim to leverage artificial intelligence technology to facilitate early screening, diagnosis, and treatment of cancer, thereby effectively reducing disease mortality rates and saving families.”

Recently, TomoDeep’s independently developed Volumetric Attention algorithm framework won the world championship in the Liver and Tumor Segmentation Challenge (LiTS). Over the past year, we have continued to innovate by optimizing algorithms for our lung cancer products and developing solutions for new indications, including chest X-rays for pulmonary diseases, mammography, CT for stroke, and CT for liver cancer. Meanwhile, we are also making breakthroughs in the areas of fracture detection, pulmonary diseases, prostate conditions, and pathology.

Tumashenwei’s Volumetric Attention Solution Wins Championship

“Tumashenwei is collaborating with nearly 300 hospitals and research institutions worldwide, with its intelligent diagnostic products assisting physicians in processing approximately 25,000 clinical cases daily. This significantly enhances diagnostic efficiency while effectively reducing misdiagnosis rates,” emphasized Zhong Xin.

CMEF: Inauguration Ceremony of the China Strategic Alliance for Intelligent Diagnosis and Treatment of Lung Cancer

In May this year, the China Intelligent Diagnosis and Treatment Strategic Alliance for Lung Cancer was established at the CMEF in Shanghai. As a key member of the alliance, TomoDeep provides a closed-loop intelligent diagnostic solution throughout the entire lung cancer diagnosis and treatment process, covering early screening, nodule detection, nodule type classification, biopsy guidance, and postoperative follow-up. Currently, TomoDeep’s Intelligent Lung Nodule Diagnosis System (σ-Discover/Lung Nodule) has entered large-scale clinical application at the Pulmonary Nodule Diagnosis and Treatment Sub-center of Shanghai International Medical Center, marking the transition of AI-based lung nodule diagnosis technology from research to clinical practice.

Emerging technologies are continuously reshaping the world, rapidly shortening the time and distance from laboratory research to commercial deployment. Tuma Shenwei is fulfilling its mission by integrating deep learning into intelligent healthcare, harnessing technology for the benefit of humanity.

Tumaini Deepwise, founded in 2015, is a high-tech enterprise dedicated to the research and development of world-leading intelligent medical imaging computer-aided diagnosis (CAD) systems and comprehensive diversified solutions. Its current product portfolio encompasses a relatively complete suite of medical imaging CAD products for pulmonary nodules, thoracic diseases, liver diseases, breast cancer, stroke, and brain tumors. The company is committed to applying artificial intelligence and deep learning technologies to multi-site, end-to-end, and multi-departmental auxiliary diagnosis, while expanding its applications into pathology, genomics, and pharmaceutical scenarios. Tumaini Deepwise’s products have been deployed in over 200 hospitals, and it has established scientific research collaborations with more than 30 top-tier domestic and international hospitals, achieving initial commercialization. The company is progressively deepening its global presence, having completed strategic expansions in the United States, Japan, and Europe. It has formed in-depth collaborations with local strategic partners, leading research institutions, and hospitals, further consolidating and strengthening its industry leadership.